Nuclear oncology and the Imagene concept.
Over the past 2 decades we have witnessed an explosion of new radioisotopic tracers aimed at detecting, staging and eventually treating tumors. In fact, nuclear oncology has evolved into a field on its own. Aside from aspecific radioisotopic tracers such as thallium 201 or gallium 67, clinicians and oncologists can now use specific radiolabeled monoclonal antibodies and metabolic tracers. In the near future, molecular probes based on the sequencing of the human genome with an exquisite specificity should also become available. In this article, we shall review the most recent developments in this new field.
Urbain
J L
JL
Department of Diagnostic Imaging, Temple University School of Medicine, Philadelphia, PA, USA. jlurbain@astro.ocis.temple.edu
Vekemans
M C
MC
Lemieux
S K
SK
Cosenza
S C
SC
Senadhi
V K
VK
Milestone
B N
BN
Reddy
E P
EP
D015894:Genome, Human; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D015335:Molecular Probes; D009683:Nuclear Medicine / Q000639:trends*; D010455:Peptides; D016719:Radioimmunodetection / Q000639:trends; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000639:trends
D015335:Molecular Probes; D010455:Peptides; D019275:Radiopharmaceuticals